scholarly journals THERAPY OF ENDOCRINE DISEASE: Islet transplantation for type 1 diabetes: so close and yet so far away

2015 ◽  
Vol 173 (5) ◽  
pp. R165-R183 ◽  
Author(s):  
Mohsen Khosravi-Maharlooei ◽  
Ensiyeh Hajizadeh-Saffar ◽  
Yaser Tahamtani ◽  
Mohsen Basiri ◽  
Leila Montazeri ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Islet Transplantation ◽  
Diabetic Patients ◽  
Immune Rejection ◽  
Pancreatic Islet Transplantation ◽  
Insulin Independence ◽  
Endocrine Disease ◽  
The Past ◽  
Source Limitation

Over the past decades, tremendous efforts have been made to establish pancreatic islet transplantation as a standard therapy for type 1 diabetes. Recent advances in islet transplantation have resulted in steady improvements in the 5-year insulin independence rates for diabetic patients. Here we review the key challenges encountered in the islet transplantation field which include islet source limitation, sub-optimal engraftment of islets, lack of oxygen and blood supply for transplanted islets, and immune rejection of islets. Additionally, we discuss possible solutions for these challenges.

scholarly journals Gene Therapy to Improve Pancreatic Islet Transplantation for Type 1 Diabetes Mellitus

2010 ◽  
Vol 6 (5) ◽  
pp. 274-284 ◽  
Author(s):  
Amy Hughes ◽  
Claire Jessup ◽  
Chris Drogemuller ◽  
Daisy Mohanasundaram ◽  
Clyde Milner ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Gene Therapy ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Islet Transplantation ◽  
Pancreatic Islet ◽  
Pancreatic Islet Transplantation

scholarly journals Reduction in Carotid Intima-Media Thickness After Pancreatic Islet Transplantation in Patients With Type 1 Diabetes

Diabetes Care ◽  
2012 ◽  
Vol 36 (2) ◽  
pp. 450-456 ◽  
Author(s):  
K. K. Danielson ◽  
B. Hatipoglu ◽  
K. Kinzer ◽  
B. Kaplan ◽  
J. Martellotto ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Islet Transplantation ◽  
Pancreatic Islet ◽  
Intima Media Thickness ◽  
Carotid Intima Media Thickness ◽  
Pancreatic Islet Transplantation ◽  
Media Thickness

First Brazilian pancreatic islet transplantation in a patient with type 1 diabetes mellitus

2004 ◽  
Vol 36 (4) ◽  
pp. 1117-1118 ◽  
Author(s):  
F.G Eliaschewitz ◽  
C.A.M Aita ◽  
T Genzini ◽  
I.L Noronha ◽  
F.H Lojudice ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Islet Transplantation ◽  
Pancreatic Islet ◽  
Pancreatic Islet Transplantation

scholarly journals Potent Induction Immunotherapy Promotes Long-Term Insulin Independence After Islet Transplantation in Type 1 Diabetes

2012 ◽  
Vol 12 (6) ◽  
pp. 1576-1583 ◽  
Author(s):  
M. D. Bellin ◽  
F. B. Barton ◽  
A. Heitman ◽  
J. V. Harmon ◽  
R. Kandaswamy ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Islet Transplantation ◽  
Insulin Independence

scholarly journals Regenerative Therapy of Type 1 Diabetes Mellitus: From Pancreatic Islet Transplantation to Mesenchymal Stem Cells

2016 ◽  
Vol 2016 ◽  
pp. 1-22 ◽  
Author(s):  
Nadine E. Rekittke ◽  
Meidjie Ang ◽  
Divya Rawat ◽  
Rahul Khatri ◽  
Thomas Linn
Keyword(s):  
Stem Cells ◽  
Type 1 Diabetes ◽  
Mesenchymal Stem Cells ◽  
Islet Transplantation ◽  
Pancreatic Islet ◽  
Graft Function ◽  
Individual Therapy ◽  
Regenerative Therapy ◽  
Pancreatic Islet Transplantation

Type 1 diabetes is an autoimmune disease resulting in the permanent destruction of pancreatic islets. Islet transplantation to portal vein provides an approach to compensate for loss of insulin producing cells. Clinical trials demonstrated that even partial islet graft function reduces severe hypoglycemic events in patients. However, therapeutic impact is restrained due to shortage of pancreas organ donors and instant inflammation occurring in the hepatic environment of the graft. We summarize on what is known about regenerative therapy in type 1 diabetes focusing on pancreatic islet transplantation and new avenues of cell substitution. Metabolic pathways and energy production of transplanted cells are required to be balanced and protection from inflammation in their intravascular bed is desired. Mesenchymal stem cells (MSCs) have anti-inflammatory features, and so they are interesting as a therapy for type 1 diabetes. Recently, they were reported to reduce hyperglycemia in diabetic rodents, and they were even discussed as being turned into endodermal or pancreatic progenitor cells. MSCs are recognized to meet the demand of an individual therapy not raising the concerns of embryonic or induced pluripotent stem cells for therapy.

Sign in / Sign up

Export Citation Format

Share Document